RxDoctor Payments Data

William Walton, MD

Ophthalmology · Live Oak, TXNPI 1134235500

Payments from drug & device makers

$2,701in general payments, 2019–2025

Across 48 payments — averaging $56.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • Alcon$565
  • AbbVie$214
  • Aerie Pharmaceuticals, Inc.$208
  • Genentech USA, Inc.$125
  • Apellis Pharmaceuticals, Inc.$125
  • plus $259 from 5 others

What the payments were for

  • Food & beverage$2,701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,701 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$466,089
Medicare patients
1,625
Services billed
4,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine55$66,169
LumiganBimatoprost64$43,402
VyzultaLatanoprostene Bunod37$18,358
Prednisolone Acetate235$12,070
RocklatanNetarsudil Mesylat/Latanoprost11$11,981
Latanoprost1,060$11,574
Bromfenac Sodium64$7,599
Travoprost50$7,320
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat457$7,181
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$6,130
MoxifloxacinMoxifloxacin Hcl228$5,969
Cyclosporine19$5,818
CombiganBrimonidine Tartrate/Timolol12$5,454
Alphagan PBrimonidine Tartrate13$4,881
IlevroNepafenac12$4,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$214$119,906144 claims
Bausch & Lomb Americas Inc.Vyzulta$17$18,35837 claims
Aerie Pharmaceuticals, Inc.Rocklatan$208$11,98111 claims
AlconSimbrinza$565$3,26212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Live Oak

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →